Karyopharm TherapeuticsKPTI -3.17%52 Gross Margin % is 96.16% as of Mar. 2026, which is 0% below its 10-year median of 96.62. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.39 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 734 Biotechnology companies, Karyopharm Therapeutics ranks better than 94.01% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Karyopharm Therapeutics had a gross margin of 96.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Karyopharm Therapeutics Gross Margin % Related Terms
Karyopharm Therapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPTI vs CHRS, TARA, CNTN: Gross Margin % Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Karyopharm Therapeutics (KPTI) has a Gross Margin % of 96.16% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Karyopharm Therapeutics and its competitors. This is near median its historical median of 96.62. Over the past decade, Karyopharm Therapeutics' Gross Margin % has ranged from 94.11 to 98.38. According to the industry distribution chart, Karyopharm Therapeutics ranks #44 out of 734 companies in the Biotechnology industry, placing it in the top 6%.
Is Karyopharm Therapeutics' Gross Margin % too high?
Karyopharm Therapeutics' current Gross Margin % of 96.16% is near median its 10-year median of 96.62. Over the past 10 years, this metric has ranged from a low of 94.11 to a high of 98.38. The Biotechnology industry median Gross Margin % is 60.80. Karyopharm Therapeutics' value of 96.16% is 58.2% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #44 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Gross Margin % compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #44 out of 734 companies for Gross Margin %. This places Karyopharm Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.80. Karyopharm Therapeutics' value of 96.16% is 58.2% above this benchmark. Historically, Karyopharm Therapeutics' own Gross Margin % has ranged from 94.11 to 98.38 over the past decade. While the company's 10-year median is 96.62 vs. the industry median of 60.80, Karyopharm Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Gross Margin % of 96.16% is 58.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Gross Margin % is 96.16%, which is near median its own 10-year median of 96.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.76 — trading 52.7% above its estimated fair value. The current Gross Margin % is 96.16%, which is near median its 10-year median of 96.62 and 58.2% above the Biotechnology industry median of 60.80. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Gross Margin % is 96.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.76 is trading 52.7% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Gross Margin %: 96.16% (near median its 10-year median of 96.62)
GF Value™: $6.39 vs. price of $9.76 (52.7% above fair value)
Industry Position: 58.2% above the Biotechnology median (#44 of 734)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
